Treatment with granulocyte colony–stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction - 21/08/11
, Hans R. Figulla, MD a, Michael Herzau, MD c, Matthias Voth, MD c, Michael Fritzenwanger, MD a, Thomas Opfermann, PhD c, Katharina Pachmann, MD b, Andreas Krack, MD a, Herbert G. Sayer, MD b, Dietmar Gottschild, MD c, Gerald S. Werner, MD aRésumé |
Background |
This study was undertaken to evaluate the hypothesis that treatment with granulocyte colony–stimulating factor (G-CSF) to mobilize bone marrow cells (BMCs) is feasible and safe and promotes neovascularization and myocardial function in patients with acute myocardial infarction.
Methods |
Fourteen patients in the treatment group and 9 patients in the control group were enrolled in this prospective, nonrandomized, open-label study. Forty-eight hours after successful recanalization and stent implantation, the patients of the treatment group received 10 μg/kg body weight per day G-CSF subcutaneously for mean treatment duration of 7.0 ± 1.0 days. Nine patients fulfilled the entry criteria but refused participation and served therefore as control group. In both groups, regional wall motion and perfusion was evaluated with electrocardiogram-gated sestamibi single-photon emission computed tomography imaging and ejection fraction with radionuclidventriculography before discharge and after 3 months.
Results |
No severe side effects of G-CSF treatment were observed. There was a significant improvement of the regional wall motion and perfusion within the treatment group (P < .0001) and between the treatment and control group (P < .05 and P < .01, respectively). Ejection fraction in the treatment group increased from 0.40 ± 0.11 to 0.48 ± 0.13 (P < .01), whereas in the control group, ejection fraction increased from 0.40 ± 0.13 to 0.43 ± 0.13 (P = .049). A control angiography of the treatment group after 12.4 ± 6.6 months showed an in-stent restenosis in 1 patient.
Conclusion |
In patients with acute myocardial infarction, treatment with G-CSF to mobilize BMCs is feasible and safe and seems to be effective under clinical conditions. The therapeutic effect might be attributed to BMC-associated promotion of myocardial regeneration and neovascularization.
Le texte complet de cet article est disponible en PDF.Plan
Vol 150 - N° 1
P. 115 - juillet 2005 Retour au numéro
Article précédent
- Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease
- Oscar C. Marroquin, Kevin E. Kip, Suresh R. Mulukutla, Paul M. Ridker, Carl J. Pepine, Tjendimin Tjandrawan, Sheryl F. Kelsey, Sunil Mankad, William J. Rogers, C. Noel Bairey Merz, George Sopko, Barry L. Sharaf, Steven E. Reis
- Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial
- The ADVANCE MI Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?